Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients

Clinical trial NCT04753203 · UNKNOWN

Trial details

NCT number: NCT04753203
Sponsor: Korean Cancer Study Group
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Colorectal Cancer PIK3CA Gene Mutation

Start date: 2021-02-28
Primary completion: 2024-02-28
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.